Wholesale Raw CBD Oil Vape Pickens South Carolina

Understanding Cannabinoids: CBN vs CBD

While there are many cannabinoids that may enhance the therapeutic effects of hemp products, the most common renowned product is the phytochemicals in the Cannabis genus that contain the tetrahydrocannabinol or THC. This is the substance that is responsible for all of the psychoactive effects of cannabis. CBD has long been associated with the variety that offers up the best help benefits without offering up the high that the THC gives to users.

While the CBD may not be the feature that is in all of the hemp products, it’s a by-product of the THC. Hemp Genix, Wholesale CBD Oil in Pickens, has 80% purity compared to competitors at 17%-40%.  The CBN doesn’t bind to the body’s cannabinoid receptors like the THC does. It’s long been known to give a stronger sedative effect when it’s used in combination with the THC.

pure cbd oil wholesale

At Hemp Genix, all of our products are made with 100 percent USA, Zero THC and 80 percent purity Wholesale full-spectrum CBD oil in Pickens. This is carefully derived from a variety of cultivars of hemp which contain an abundance of cannabinoids.

A lot of people are very familiar with CBD or Cannabidiol. This is found in highly concentrated amounts in a variety of products. However, there are lots of cannabinoids that are found in hemp. These have shown a variety of benefits in studies. All of our products offer you full-spectrum hemp oil. This also includes all of our cannabinoids that are found in the plant. We don’t want you to miss out on any of the benefits.

 

Wholesale Cannabidiol CBD in Pickens

This is the most abundant cannabinoid in the hemp oil. It makes up 90 percent of the content of cannabinoid. It’s non-psychoactive and the focus is on how it benefits the body via the hemp oil. It has minimal affinity for CB1 or CB2 receptors. The main focus on interaction is in the endocannabinoid system and it acts as an indirect antagonist toward the cannabinoid antagonists. This, in turn, may allow the CBD to temper the high that is caused through the THC. Wholesale CBD Oil in Pickens from Hemp Genix are over 80 percent pure and CBD makes up the majority of the Oils weight. Industry averages and nearly all of the other products with cannabinoids and brands average in at 17 to 40 percent purity.

cbd hemp oil vape wholesale

What’s The Difference Between CBD And CBN?

Cannabis has a number of cannabinoids in which the most abundant are the levels of THC. There are 9 tetrahydrocannabinol as well as CBD and CBN. This is the active ingredient that makes you high. The THC is in the plant and the CBD is the precursor and the CBN is the metabolite of the THC. As the cannabis ages, the THC level breaks down into the CBN.

 

This also leads researchers to believe that the CBD might give some protection against ecstasy-derived neurotoxins or long-term depletion of the serotonergic receptions. While this is still speculation, it’s investigating further. The CBD is usually present in significant enough quantities in such products as hashish or cannabis resins. However,r it’s also in the herbal cannabis referred to as skunk in smaller amounts.

Overall, the CBN is a great cannabinoid that offers up a varied range of therapeutic applications that work together with the rest of the “team” in order to offer up the best possible results. Clearly, more clinical trials are required to see how else it can benefit patients.

wholesale cbd oil zamnesia

Wholesale CBD Oil in Pickens South Carolina

In a historic move, the U.S. Drug Enforcement Agency granted approval for a nonprofit to study marijuana's medical benefits on military veterans suffering from combat-related psychological disorders.

The Multidisciplinary Association for Psychedelic Studies (MAPS), a California-based nonprofit that studies medical uses of psychotropic drugs, will conduct the clinical trial, which will be a double-blind, placebo-controlled trial using the whole plant (not an extract or pill version). The trial is the first in U.S. history to receive full approval from the DEA and FDA.

The study will examine whether medical marijuana can treat Post-Traumatic Stress Disorder in 76 U.S. military veterans. The veterans have treatment-resistant PTSD and haven't found relief from other medications. The study will look into how different strains and doses of marijuana can benefit the veterans and look into potential side effects, a press release from MAPS says.

The trial intends to develop "smoked botanical marijuana into a legal prescription drug" approved by the FDA, MAPS says in a statement.

MAPS received a $2.16 million grant from Colorado's Department of Public Health and Environment (CDPHE) to conduct the trial.

"We have been working towards approval since we opened the Investigational New Drug Application (IND) with the FDA in 2010," said Amy Emerson, executive director and director of clinical research for the MAPS Public Benefit Corporation, in a release. "We are thrilled to see this study overcome the hurdles of approval so we can begin gathering the data. This study is a critical step in moving our botanical drug development program forward at the federal level to gather information on the dosing, risks, and benefits of smoked marijuana for PTSD symptoms."

MAPS, which was founded in 1986, has raised over $36 million for psychedelic therapy and research and education in marijuana's medical benefits.

The Trump Administration Puts the Recreational Marijuana Industry on Notice With New Enforcement Stance

In a historic move, the U.S. Drug Enforcement Agency granted approval for a nonprofit to study marijuana's medical benefits on military veterans suffering from combat-related psychological disorders.

The Multidisciplinary Association for Psychedelic Studies (MAPS), a California-based nonprofit that studies medical uses of psychotropic drugs, will conduct the clinical trial, which will be a double-blind, placebo-controlled trial using the whole plant (not an extract or pill version). The trial is the first in U.S. history to receive full approval from the DEA and FDA.

The study will examine whether medical marijuana can treat Post-Traumatic Stress Disorder in 76 U.S. military veterans. The veterans have treatment-resistant PTSD and haven't found relief from other medications. The study will look into how different strains and doses of marijuana can benefit the veterans and look into potential side effects, a press release from MAPS says.

The trial intends to develop "smoked botanical marijuana into a legal prescription drug" approved by the FDA, MAPS says in a statement.

MAPS received a $2.16 million grant from Colorado's Department of Public Health and Environment (CDPHE) to conduct the trial.

"We have been working towards approval since we opened the Investigational New Drug Application (IND) with the FDA in 2010," said Amy Emerson, executive director and director of clinical research for the MAPS Public Benefit Corporation, in a release. "We are thrilled to see this study overcome the hurdles of approval so we can begin gathering the data. This study is a critical step in moving our botanical drug development program forward at the federal level to gather information on the dosing, risks, and benefits of smoked marijuana for PTSD symptoms."

MAPS, which was founded in 1986, has raised over $36 million for psychedelic therapy and research and education in marijuana's medical benefits.


South Carolina Wholesale CBD Oil Facilities

Home